Literature DB >> 17868248

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.

Guido Cavaletti1, Barbara Frigeni, Francesca Lanzani, Marialuisa Piatti, Stefania Rota, Chiara Briani, Gabriella Zara, Rosaria Plasmati, Francesca Pastorelli, Augusto Caraceni, Andrea Pace, Mariagrazia Manicone, Andrea Lissoni, Nicoletta Colombo, Giulia Bianchi, Claudio Zanna.   

Abstract

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major side effect of several antineoplastic drugs. However, despite its clinical importance, there is no agreement as to the best way to assess the severity and changes in CIPN. We have previously demonstrated a correlation between the severity of CIPN, assessed using the Total Neuropathy Score (TNS) or its reduced versions, and several common toxicity scales. In this study, we investigated two series of patients (total number = 173) who were evaluated at baseline and during chemotherapy with the TNS (n= 122) or the TNSc (the TNS version based exclusively on the clinical evaluation of the patients, n= 51) and with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) 2.0, with the aim of comparing the sensitivity to the changes in CIPN severity. In both series, the TNS and the TNSc had a significant correlation with the NCI-CTC in scoring the severity of CIPN, confirming the results of previous studies. Moreover, both the TNS and the TNSc showed a higher sensitivity to CIPN changes. We, therefore, propose the TNSc as a reliable method for assessing not only the severity but also the changes in CIPN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868248     DOI: 10.1111/j.1529-8027.2007.00141.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  77 in total

1.  Lenalidomide for bortezomib-resistant multiple myeloma.

Authors:  Chiara Briani; Tamara Berno; Marta Campagnolo; Renato Zambello
Journal:  Nat Rev Clin Oncol       Date:  2010-09       Impact factor: 66.675

Review 2.  Peripheral neuropathy: clinical and electrophysiological considerations.

Authors:  Tae Chung; Kalpana Prasad; Thomas E Lloyd
Journal:  Neuroimaging Clin N Am       Date:  2013-05-25       Impact factor: 2.264

3.  Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients.

Authors:  Sarah Besora; Cristina Santos; Cristina Izquierdo; Maria Mercedes Martinez-Villacampa; Jordi Bruna; Roser Velasco
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-28       Impact factor: 4.553

4.  Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes.

Authors:  Tejaswi Kandula; Michelle Anne Farrar; Richard J Cohn; David Mizrahi; Kate Carey; Karen Johnston; Matthew C Kiernan; Arun V Krishnan; Susanna B Park
Journal:  JAMA Neurol       Date:  2018-08-01       Impact factor: 18.302

5.  Vitamin E for preventing chemotherapy-induced peripheral neuropathy.

Authors:  Andreas A Argyriou; Haralabos P Kalofonos
Journal:  Support Care Cancer       Date:  2011-01-14       Impact factor: 3.603

6.  Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.

Authors:  J Matt McCrary; David Goldstein; David Wyld; Robert Henderson; Craig R Lewis; Susanna B Park
Journal:  J Cancer Surviv       Date:  2019-06-06       Impact factor: 4.442

Review 7.  Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith
Journal:  Semin Oncol Nurs       Date:  2019-04-30       Impact factor: 2.315

8.  Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy.

Authors:  Delma Aurélia da Silva Simão; Antônio Lúcio Teixeira; Raissa Silva Souza; Elenice Dias Ribeiro de Paula Lima
Journal:  Support Care Cancer       Date:  2014-05-09       Impact factor: 3.603

9.  Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia.

Authors:  Sindhu Ramchandren; Marcia Leonard; Rajen J Mody; Janet E Donohue; Judith Moyer; Raymond Hutchinson; James G Gurney
Journal:  J Peripher Nerv Syst       Date:  2009-09       Impact factor: 3.494

10.  Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study.

Authors:  Kirsten K Ness; Kendra E Jones; Webb A Smith; Sheri L Spunt; Carmen L Wilson; Gregory T Armstrong; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; James G Gurney
Journal:  Arch Phys Med Rehabil       Date:  2013-03-26       Impact factor: 3.966

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.